Wednesday, 29 July 2026
Itvisma gene therapy approved in EU, Orlistat kidney injury warnings, Rextovy nasal spray for overdoses
- 01
Itvisma gene therapy for spinal muscular atrophy authorised in EU
The European Medicines Agency has authorised Itvisma, a gene therapy for treating spinal muscular atrophy (SMA) in patients aged 2 years and older with specific genetic mutations. Itvisma, containing the active substance onasemnogene abeparvovec, aims to improve motor function by providing a functional copy of the SMN1 gene. The therapy is administered via a single intrathecal injection and requires careful monitoring and corticosteroid treatment. This approval could significantly enhance treatment options for SMA patients in Australia.
- 02
FDA Warns of Kidney Injury Risks with Orlistat
The US Food and Drug Administration (FDA) has updated the labeling for the over-the-counter weight-loss drug orlistat to include warnings about the risk of acute kidney injury. This change aims to inform consumers and healthcare providers about potential safety concerns associated with the medication. The addition of this warning may influence prescribing practices and patient counseling regarding orlistat.
via JAMA
- 03
FDA Approves Rextovy Nasal Spray for Opioid Overdose
The US Food and Drug Administration (FDA) has approved a new over-the-counter intranasal naloxone product, Rextovy, for the emergency treatment of opioid overdose. This approval expands the availability of naloxone, a critical medication for addressing opioid-related incidents. The introduction of Rextovy may enhance access to emergency care for individuals experiencing opioid overdoses.
via JAMA
- 04
WHO Releases Comprehensive Guidelines for Ebola and Marburg Treatment
The World Health Organization (WHO) has issued its first comprehensive guidelines for the clinical management of filovirus diseases, encompassing all Ebola and Marburg viruses. This development aims to provide critical updates for clinicians involved in the treatment of these infectious diseases.
via JAMA
- 05
Resistance Training Reduces Cardiovascular Disease Risk in Women
New research indicates that resistance training is linked to a lower risk of cardiovascular disease (CVD) in women. This finding may have implications for preventive health strategies. The study highlights the potential benefits of incorporating strength training into women's health regimens.
via JAMA
- 06
Correction Issued for Oncology Biosimilars Pricing Study
JAMA has issued a correction to the Original Investigation titled "Hospital Adoption and Pricing for Oncology Biosimilars," published on March 11, 2026. The correction pertains to adjustments made in the Discussion section regarding how Medicare marks up the acquisition of oncology biosimilars compared to biologics. This update is significant for understanding the financial implications of biosimilar adoption in oncology settings.
via JAMA
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.